Using an app to track nutrition in head and neck cancer patients during treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with squamous cell carcinoma of the head and neck who are undergoing radio(chemo)therapy. Participants will use the Emento app to record their nutritional status and diet throughout the treatment and for eight weeks post-therapy. The app sends daily reminders to encourage adequate caloric intake and includes bi-weekly screening questions to monitor health and nutritional status. If any negative responses are recorded, the study protocol ensures that the patient is promptly referred to their healthcare provider for further evaluation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with squamous cell carcinoma in the head and neck region, who receive a postsurgical or definitive radio(chemo)therapy
* Patients who have a smartphone on which the Emento app can be installed
* Minimum age 18 years

Exclusion Criteria:

* Patients who are represented by a legal guardian
* Patients who are not suitable for participation in the study due to a language barrier

Where it's running

• Universitätsklinikum Erlangen, Strahlenklinik
  Erlangen, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Allison Lamrani — Universitätsklinikum Erlangen, Radiation Oncology
• Study coordinator: Studiensekretariat
• Email: studiensekretariat.ST@uk-erlangen.de
• Phone: +49913185

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Iparomlimab plus tuvonralimab, with or without chemotherapy, for second-line and later recurrent or metastatic head and neck squamous cell carcinoma

  This will try whether combining two antibodies, iparomlimab and tuvonralimab, with or without chemotherapy helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after at least one systemic treatment.

  Recruiting The Second Affiliated Hospital of Hainan Medical University · Haikou, Hainan · NCT07546383

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Neoadjuvant CADI-05 with pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma

  This will test whether adding weekly CADI-05 skin injections to pembrolizumab before surgery helps adults with resectable locally advanced head and neck squamous cell cancer.

  Recruiting at 2 sites Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania and 1 other locations · NCT07455032

• 5-Fluorouracil Response and Optimization (FROST)

  This trial will test two different dosing schedules of 5‑fluorouracil as second-line-or-later treatment for people with recurrent or metastatic head and neck squamous cell carcinoma who have already had platinum and PD‑1 inhibitor therapy.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07419464

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.